Portal de Periódicos da CAPES

Impact of Biological Agents on Postsurgical Complications in Inflammatory Bowel Disease: A Multicentre Study of Geteccu

2021; Multidisciplinary Digital Publishing Institute; Volume: 10; Issue: 19 Linguagem: Inglês

10.3390/jcm10194402

2077-0383

María José García, Montserrat Rivero, José Miranda-Bautista, Iria Bastón‐Rey, Francisco Mesonero, Eduardo Leo‐Carnerero, Diego Casas Deza, Carmen Cagigas Fernández, Albert Martín‐Cardona, Ismael El Hajra, Nerea Hernández-Aretxabaleta, Isabel Pérez‐Martínez, Esteban Fuentes-Valenzuela, Nuria Jiménez, Cristina Rubín de Célix, Ana Gutiérrez, Cristina Suárez Ferrer, José María Huguet, A Fernández-Clotet, M González-Vivó, Blanca Del Val, Jesús Castro‐Poceiro, Luigi Melcarne, Carmen Dueñas, M. Izquierdo, David Monfort, Abdel Bouhmidi, Patricia Ramírez de la Piscina, E Romero, Gema Molina, Jaime Zorrilla, Cristina Suárez, Eugenia Sánchez, A. Rodriguez Nunez, O. Sierra, Beatriz Castro, Yamile Zabana, Irene González-Partida, Saioa de la Maza, Argelia Castaño, Rodrigo Nájera-Muñoz, Luis Sánchez‐Guillén, Micaela Riat Castro, J L Rueda García, J M Benítez, Pedro Delgado‐Guillena, Carlos Tardillo, Elena Peña, Santiago Frago‐Larramona, M C Rodríguez-Grau, Rocío Plaza, Pablo Pérez-Galindo, J Martínez-Cadilla, Luís Menchén, Manuel Barreiro–de Acosta, Rubén Sánchez-Aldehuelo, María Dolores De la Cruz, Luis Javier Lamuela, Ignacio Marı́n, Laura Nieto‐García, Antonio López-San Román, José M. Herrera, María Chaparro, Javier P. Gisbert,

Eosinophilic Esophagitis

The impact of biologics on the risk of postoperative complications (PC) in inflammatory bowel disease (IBD) is still an ongoing debate. This lack of evidence is more relevant for ustekinumab and vedolizumab.To evaluate the impact of biologics on the risk of PC.A retrospective study was performed in 37 centres. Patients treated with biologics within 12 weeks before surgery were considered "exposed". The impact of the exposure on the risk of 30-day PC and the risk of infections was assessed by logistic regression and propensity score-matched analysis.A total of 1535 surgeries were performed on 1370 patients. Of them, 711 surgeries were conducted in the exposed cohort (584 anti-TNF, 58 vedolizumab and 69 ustekinumab). In the multivariate analysis, male gender (OR: 1.5; 95% CI: 1.2-2.0), urgent surgery (OR: 1.6; 95% CI: 1.2-2.2), laparotomy approach (OR: 1.5; 95% CI: 1.1-1.9) and severe anaemia (OR: 1.8; 95% CI: 1.3-2.6) had higher risk of PC, while academic hospitals had significantly lower risk. Exposure to biologics (either anti-TNF, vedolizumab or ustekinumab) did not increase the risk of PC (OR: 1.2; 95% CI: 0.97-1.58), although it could be a risk factor for postoperative infections (OR 1.5; 95% CI: 1.03-2.27).Preoperative administration of biologics does not seem to be a risk factor for overall PC, although it may be so for postoperative infections.